British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada.
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
Schizophr Res. 2019 Jul;209:198-205. doi: 10.1016/j.schres.2019.04.020. Epub 2019 Jun 27.
Schizophrenia is a severe mental illness with important implications for morbidity and mortality. This population-based cohort study examined the impact of schizophrenia diagnoses on all-cause mortality among a sample of people living with HIV (PLHIV) and a 10% random sample of individuals living without HIV (HIV-) in British Columbia (BC), through a data linkage between the BC Centre for Excellence in HIV/AIDS and Population Data BC's data holdings. Schizophrenia diagnoses were identified via International Classification of Diseases version 9 and version 10 codes. Age- and sex-adjusted all-cause mortality rates from January 1st, 1998 to December 31st, 2012 were calculated. Multivariable logistic models assessed (1) HIV status and mortality among individuals diagnosed with schizophrenia, (2) schizophrenia diagnosis and mortality among PLHIV, and (3) correlates of mortality among PLHIV concurrently diagnosed with schizophrenia (HIV+/SZO+). From 1998 to 2012, 6.3% of those with HIV had a schizophrenia diagnosis, compared to 1.1% of those without HIV. While significant declines in mortality rates were observed throughout the study period, mortality rates were highest among HIV+/SZO+. After adjustment for substance use disorder and age at baseline, HIV+/SZO+ had a 2.64 times greater odds of mortality (95% confidence interval [CI] = 2.14-3.25) compared to HIV-/SZO+. For PLHIV, a schizophrenia diagnosis was not associated with mortality after controlling for potential confounders (adjusted odds ratio [aOR] = 0.90, 95%CI = 0.74-1.09). Among HIV+/SZO+, age, history of injection drug use, ever having an AIDS-defining illness, and never being on anti-psychotic medication or accessing psychiatric services were associated with mortality. Efforts should be made to identify and link to care individuals disproportionately affected by schizophrenia and excess mortality, including those living with HIV.
精神分裂症是一种严重的精神疾病,对发病率和死亡率有重要影响。这项基于人群的队列研究通过不列颠哥伦比亚省(BC)艾滋病卓越中心和人口数据 BC 数据的链接,检查了在 HIV 阳性(PLHIV)人群和 10%的 HIV 阴性(HIV-)人群样本中,精神分裂症诊断对全因死亡率的影响。精神分裂症诊断是通过国际疾病分类第 9 版和第 10 版代码确定的。计算了 1998 年 1 月 1 日至 2012 年 12 月 31 日的年龄和性别调整后的全因死亡率。多变量逻辑模型评估了(1)HIV 状态和精神分裂症患者的死亡率,(2)PLHIV 中的精神分裂症诊断和死亡率,以及(3)同时诊断为 HIV+/SZO+的 PLHIV 的死亡率相关因素。从 1998 年到 2012 年,6.3%的 HIV 患者被诊断为精神分裂症,而 HIV 阴性患者的比例为 1.1%。虽然在整个研究期间死亡率显著下降,但 HIV+/SZO+的死亡率最高。在调整物质使用障碍和基线年龄后,与 HIV-/SZO+相比,HIV+/SZO+的死亡率高出 2.64 倍(95%置信区间[CI] = 2.14-3.25)。对于 PLHIV,在控制潜在混杂因素后,精神分裂症诊断与死亡率无关(调整后的比值比[aOR] = 0.90,95%CI = 0.74-1.09)。在 HIV+/SZO+中,年龄、既往注射吸毒史、曾经患有艾滋病定义性疾病、从未服用抗精神病药物或获得精神科服务与死亡率有关。应努力识别和联系受精神分裂症和超额死亡率不成比例影响的个体,包括那些与 HIV 共病的个体,并为他们提供治疗。